Source: Telegraph
An additional 300,000 girls aged 17 and 18 are to be offered a controversial vaccine to protect them against the sexually-transmitted infection that can lead to cervical cancer, the Government has announced.
The girls, who will be offered the Cervarix vaccine from this September, would not have been eligible for it before the announcement.
Miss Primarolo said the £10 million one-off programme would save up to 400 lives.
How does she know? None of these vaccines have guarantees.
Dawn Primarolo, the health minister, said: “Our policy to vaccinate girls against cervical cancer is one of the biggest public health campaigns in recent history. It will mean that up to 400 girls’ lives will be saved each year.
“By choosing the right vaccine we have been able to make savings which means we can extend the programme to 17 and 18 year olds. This could save an additional 400 lives.”
They are not saving money. They are spending less of our money. But they are still giving our money to these corporations.
But medics and health campaigners have accused such commentators of wilfully ignoring that teenage sex happens. They have said denying girls an HPV vaccine is morally wrong.
Bullsh*t.
Vaccinating against HPV in order to prevent cervical cancer? They obviously haven’t seen this report, from The Great Vaccine Hoax Exposed;
For the last several years, HPV vaccines have been marketed to the public and mandated in compulsory injections for young girls in several states based on the idea that they prevent cervical cancer. Now, NaturalNews has obtained documents from the FDA and other sources (see below) which reveal that the FDA has been well aware for several years that Human Papilloma Virus (HPV) has no direct link to cervical cancer.
NaturalNews has also learned that HPV vaccines have been proven to be flatly worthless in clearing the HPV virus from women who have already been exposed to HPV (which includes most sexually active women), calling into question the scientific justification of mandatory “vaccinate everyone” policies.
The Department of Health has refused to reveal the cost of the vaccine. Miss Power said GSK must have given a “considerable reduction” to win the deal. – End of source.
Unbelievable. It’s none of our business what they spend our money on apparently.
So, not only 12 and 13 year old’s, but by ‘saving money’ they will also try and inject 17 and 18 year old’s then the additional ‘top up’ for 14 and 18 year old’s in 2009. That’s three rounds of injections against a virus that most probably does not cause cervical cancer.
Glaxo’s balance sheet must be looking pretty healthy. They are still trying to get the vaccine approved in the U.S. as I write this, as Reuters reports;
Glaxo said it had responded to outstanding questions about Cervarix raised by the U.S. Food and Drug Administration but had decided to augment its application with results from a further Phase III study, called HPV-008.
Data from this trial are expected to be submitted to the U.S. regulator in the first half of 2009 and an FDA decision on the application is anticipated up to six months later.
Analysts, however, say the FDA is extremely cautious about approving new adjuvants because of the theoretical risk of side effects, increasing the regulatory hurdle for Glaxo’s vaccine.
Side effects? Nah, get out of here!
From European Public Assessment Report, Product Information PDF;
Side effects that occurred during clinical trials with Cervarix were as follows:
♦ Very common (side effects which may occur in more than 1 per 10 doses of vaccine):
• pain or discomfort at the injection site
• redness or swelling at the injection site
• headache
• aching muscles, muscle tenderness or weakness (not caused by exercise)
• tiredness
♦ Common (side effects which may occur in less than 1 per 10 but more than 1 per 100 doses of
vaccine):
• gastrointestinal symptoms including nausea, vomiting, diarrhoea and abdominal pain
• itching, red skin rash, hives (urticaria)
• joint pain
• fever (≥38°C)
♦ Uncommon (side effects which may occur in less than 1 per 100 but more than 1 per 1,000
doses of vaccine):
• upper respiratory tract infection (infection of the nose, throat or trachea)
• dizziness
• other injection site reactions such as hard lump, tingling or numbness.
A look at Cervarix ingredients, from the same document;
The active substances are:
Human Papillomavirus1 type 16 L1 protein2,3,4 20 micrograms
Human Papillomavirus1 type 18 L1 protein2,3,4 20 micrograms
adjuvanted by AS04 containing: 3-O-desacyl-4’- monophosphoryl lipid A (MPL)3 50 micrograms
adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+ in total
L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant
DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived
from the insect Trichoplusia ni.
– The other ingredients are sodium chloride (NaCl), sodium dihydrogen phosphate dihydrate
(NaH2PO4.2 H2O) and water for injections.
Some samples from the Scientific Discussion PDF that stand out to me (as a layman, obviously);
No pharmacodynamic drug interaction studies were performed according to the Note for Guidance on Preclinical Pharmacological and Toxicological testing of vaccines (CPMP/465/95) and Guideline on Adjuvants in Vaccines for Human Use (EMEA/CHMP/VEG/134716/2004).
Studies to demonstrate absorption, distribution, metabolism, and excretion of the active ingredients in Cervarix have not been performed for any of the component viruses. This is in line with Note for guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP/SWP/465/95).
Single-dose toxicity of the HPV-16/18 L1 VLP AS04 vaccine was assessed as part of the repeat-dose toxicity study in rabbits. The treatment was well tolerated and no treatment-related systemic effect was noticed on haematology, body-weight, clinical signs, mortality and clinical chemistry over a 14-day observation period.
According to the Note for Guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP/SWP/465/95) and the Guideline on adjuvants in vaccines for human use
(EMEA/CHMP/VEG/134716/2004) genotoxicity studies are not required for this vaccine.
According to the Note for Guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP/SWP/465/95) and the Guideline on adjuvants in vaccines for human use
(EMEA/CHMP/VEG/134716/2004) carcinogenicity studies are not required for this vaccine.
It’s 56 pages long, so I’m not going to go through it all here. I have provided the link above anyway if anyone is interested. Before I finish this however, I have one more query.
From the Discussion (to find these notes in the PDF, try copying and pasting one of the sentences into the PDF program search engine, that should take you right to it);
Based on their genomic differences within the oncogenes E6 and E7 and the capsid protein L1 over 100 genotypes are described to date. Thereof approximately 40 different genotypes lead to infections of the anogenital tract and about 16 are highly oncogenic with HPV types 16 and 18, being the most frequent found in cervical cancer. HPV-16 is detected in about 54% of cervical cancer cases, and the second type is HPV-18, detected in about 17% of cases.
The time from occurrence of HPV infection to cancer development usually exceeds 20 years.
However, persistent HPV infection is a necessary but not a sufficient factor for the development of cervical carcinoma. (what?) Other factors such as smoking, long-term use of oral contraceptives or high parity are suggested to play a role in the process that lead to cancer.
This next part is good;
The majority of genital HPV infections (>90%) however are transient sub-clinical infections that will be cleared or suppressed below the limits of detection by host cell defences within one to two years. In addition, any cervical lesion may spontaneously regress to normal without treatment with a probability of about 57% for CIN1, 43% for CIN2 and 32% for CIN3. The determinants leading to regression are not well understood.
Even according to this document, HPV isn’t looking much of a threat to me. Still they say this:
It is confirmed that persistent cervical infection by high risk HPV types is a precursor event to cervical cancer.
There was no evidence of protection from disease caused by the HPV types for which subjects were HPV DNA positive at study entry. However, individuals already infected with one of the vaccine-related HPV types prior to vaccination were protected from clinical disease caused by the remaining HPV type.
From the Product Information Report (again);
The duration of protection after vaccination is currently unknown. In clinical trials, sustained
protection has been observed in females aged 15 to 25 years for at least 5.5 years after the first dose. The need for booster dose(s) has not been investigated.
I hope you know, the average age of cervical cancer patients is 48. They want to give this vaccine to 12 year olds, although it lasts only 5.5 years? Why?
MONEY.
I feel stupid, I have a feeling I’m missing something here.
According to these documents, this vaccine ‘protects’ against two strains of HPV, of which there are over 100. They say that in patients that have been diagnosed with cervical cancer, HPV can be present (that is not evidence of causation.) Even then HPV 16 turns up 56% of the time, and HPV 18, 17%. It then says that other things can cause cervical cancer anyway. It doesn’t protect you if you already have HPV! Not that HPV causes the cancer. The body successfully deals with over 90% of HPV viruses anyway.
Somehow I don’t see the huge cost justified by these reports (of which I have barely skimmed.) These politicians are probably getting kick backs, it wouldn’t be the first time.
Gardasil vaccine deaths in UK
HPV Vaccine Hoax Exposed
HPV Vaccine Gardasil 2
HPV Vaccine Gardasil
FDA and HPV — when did they know the truth?
End of Men 